ライフサイエンスコーパス: histoplasmosis

1 is, chronic herpes simplex, and disseminated histoplasmosis).

2 ncy were reclassified as benign (thymoma and histoplasmosis).

3 eeded for pneumocystosis, talaromycosis, and histoplasmosis.

4 similar role to play in the pathogenesis of histoplasmosis.

5 igen to protect mice in a model of pulmonary histoplasmosis.

6 n the lungs of C57BL/6 mice with reinfection histoplasmosis.

7 locker therapy after successful treatment of histoplasmosis.

8 en these receptors for regulation reexposure histoplasmosis.

9 means of diagnosing the more severe forms of histoplasmosis.

10 he course of primary and secondary pulmonary histoplasmosis.

11 ferences in control of primary and secondary histoplasmosis.

12 with sera of healthy patients or those with histoplasmosis.

13 a virulence in a murine model of respiratory histoplasmosis.

14 of a protective immune response in pulmonary histoplasmosis.

15 opment of specific serodiagnostic assays for histoplasmosis.

16 UAg) detection is an important biomarker for histoplasmosis.

17 se with different clinical manifestations of histoplasmosis.

18 r during lung infection in a murine model of histoplasmosis.

19 ility of Cfp4 as a diagnostic exoantigen for histoplasmosis.

20 after SOT is the period of highest risk for histoplasmosis.

21 series of patients undergoing treatment for histoplasmosis.

22 ere disease were risk factors for death from histoplasmosis.

23 the interplay between TNF-alpha and CCR5 in histoplasmosis.

24 ncover how innate immunity modulation alters histoplasmosis.

25 imal method for diagnosis of acute pulmonary histoplasmosis.

26 nction, resulting in an inability to control histoplasmosis.

27 e existence a regulatory IL-17/IL-23 axis in histoplasmosis.

28 ectious complications including disseminated histoplasmosis.

29 y represents a strategy of immunotherapy for histoplasmosis.

30 capsulatum, a pathogenic fungus that causes histoplasmosis.

31 ct on host resistance in mice with secondary histoplasmosis.

32 aling has on host defenses against pulmonary histoplasmosis.

33 The same is true for histoplasmosis.

34 surgery, one had arm cellulitis, and one had histoplasmosis.

35 IL-4 in the lung on the course of pulmonary histoplasmosis.

36 e most sensitive and rapid means to diagnose histoplasmosis.

37 and mycological tests to accurately diagnose histoplasmosis.

38 , subverted protective immunity in secondary histoplasmosis.

39 rapy are at risk for developing disseminated histoplasmosis.

40 reactions occurred in 96.3% of patients with histoplasmosis, 100% of patients with paracoccidioidomyc

41 t reactivity with sera from 20 patients with histoplasmosis, 15 patients with blastomycosis, and 14 h

42 ; cryptococcosis, 76% and 4 (5.80/1.35); and histoplasmosis, 68% and 6 (1.36/0.23).

43 Of the 10 patients with histoplasmosis, 9 required treatment in an intensive car

44 Furthermore, in secondary histoplasmosis, a sharp contrast can be drawn between lu

45 Histoplasmosis, a systemic mycosis caused by the fungus

46 ent, diagnosis, and outcomes associated with histoplasmosis after solid organ transplant (SOT), we re

47 In a lethal model of histoplasmosis, all PD-1-deficient mice survived infecti

48 In December 1993, four reported cases of histoplasmosis among employees in a Michigan pulp paper

49 lting in two (3.3%) deaths from disseminated histoplasmosis and a herpes virus infection.

50 Approaches to the diagnosis of histoplasmosis and areas that require further research w

51 of serum from patients with acute pulmonary histoplasmosis and controls in the MVista Histoplasma an

52 specimens from patients with culture-proven histoplasmosis and controls were tested using both metho

53 neovascularization caused by presumed ocular histoplasmosis and demonstrated stabilization of the cho

54 rement can be useful for diagnosing systemic histoplasmosis and for monitoring treatment response, es

55 ing the initial host-pathogen interaction in histoplasmosis and have revealed an important mechanism

56 choroidal neovascular membrane due to ocular histoplasmosis and to provide a treatment algorithm.

57 its reactivity with sera from patients with histoplasmosis and, to lesser extent, blastomycosis.

58 ns (cryptococcosis), Histoplasma capsulatum (histoplasmosis), and Talaromyces (Penicillium) marneffei

59 arget of the cellular immune response during histoplasmosis, and immunization with this protein is pr

60 diate protection in a murine model of lethal histoplasmosis, and it suggests a new candidate antigen

61 omaviruses, and fungal infections, primarily histoplasmosis, and molds.

62 0 confers a salutary effect on the course of histoplasmosis, and the beneficial effects of IL-10 defi

63 is, and Histoplasma capsulatum, the agent of histoplasmosis, are known to form meiotic (sexual) stage

64 will likely be of benefit in presumed ocular histoplasmosis associated choroidal neovascularization.

65 In patients with moderate to severe histoplasmosis associated with AIDS, the preferred treat

66 ide (25.0%) versus outside (28.7%) the U.S. "histoplasmosis belt." Aggregate sensitivity was 96.5% fo

67 pective review of 98 patients diagnosed with histoplasmosis between January 2000 and June 2011.

68 Clinical differences in histoplasmosis between North America and Brazil prompted

69 tion against use of AmB+Flu for treatment of histoplasmosis, but studies of the effect of treatment o

70 ing regulates pathogen persistence in murine histoplasmosis by regulating Tregs exiting from the thym

71 Acute pulmonary histoplasmosis can be severe, especially following heavy

72 Both paracoccidioidomycosis and histoplasmosis can mimic several infectious and non-infe

73 We present a case of disseminated histoplasmosis, complicated by retroperitoneal bleeding

74 nd from biopsy specimens from a patient with histoplasmosis contained fungal cells that were labeled

75 ed stored urine from patients diagnosed with histoplasmosis during an outbreak in Indianapolis which

76 pdate on findings concerning presumed ocular histoplasmosis etiology, epidemiology, and pathophysiolo

77 of-concept study may aid in the diagnosis of histoplasmosis from FFPE tissue.

78 stating vision loss that may occur in ocular histoplasmosis from the development of an atrophic scar

79 mine if IFN-gamma is necessary in reexposure histoplasmosis, GKO and WT mice were inoculated with 10(

80 Since disseminated histoplasmosis has emerged as a difficult clinical entit

81 on may be a mechanism for the development of histoplasmosis in AIDS.

82 with acquired immunodeficiency syndrome and histoplasmosis in Brazil and United States were compared

83 igen that may be useful for the diagnosis of histoplasmosis in humans.

84 While pulmonary involvement of histoplasmosis in immune-suppressed patients is common,

85 omodulatory effects of IL-12 on disseminated histoplasmosis in immunodeficient SCID mice.

86 -gamma is requisite for control of pulmonary histoplasmosis in naive and reexposed mice.

87 fy all reports received through July 2001 of histoplasmosis in patients treated with either inflixima

88 modulates the protective immune response to histoplasmosis in SCID mice and also suggests that IL-12

89 All cases of histoplasmosis in SOT recipients diagnosed between 1 Jan

90 Clinicians should consider CNS histoplasmosis in the differential diagnosis in atypical

91 he time of death can result in donor-derived histoplasmosis in the recipient.

92 es in 88.8% of patients with acute pulmonary histoplasmosis in this assay, while immunodiffusion, com

93 Using a mouse model of histoplasmosis in which both Th1 and Th17 responses cont

94 de a framework for the early pathogenesis of histoplasmosis in which yeast cell invasion of lung MPhi

95 ularization in patients with presumed ocular histoplasmosis, in particular that of subfoveal localiza

96 cases of opportunistic infection, including histoplasmosis, in patients treated with these products.

97 four significant adverse events: a suspected histoplasmosis infection; two Tenchkoff dialysis cathete

98 Presumed ocular histoplasmosis involves the classic triad of discrete at

99 Histoplasmosis is a common infection endemic in many reg

100 Histoplasmosis is a common infection in the central Unit

101 Histoplasmosis is an important systemic fungal infection

102 The diagnosis of histoplasmosis is based on a multifaceted approach that

103 Isolated CNS histoplasmosis is exceedingly rare.

104 gal meningitis, its role in the treatment of histoplasmosis is hampered by reduced activity and poten

105 Reactivation histoplasmosis is largely a result of impaired immunity,

106 The outcome of central nervous system (CNS) histoplasmosis is often unfavorable.

107 s included serious infections, tuberculosis, histoplasmosis, listeriosis, and malignancy.

108 illance suggests that acute life-threatening histoplasmosis may complicate immunotherapy with TNFalph

109 Histoplasmosis may complicate tumor necrosis factor (TNF

110 In murine histoplasmosis, mice lacking CCR5 or endogenous CCL4 hav

111 kDa (Hsp60) that modify disease in a murine histoplasmosis model.

112 ar manifestations of malaria, cysticercosis, histoplasmosis, mucormycosis, subacute sclerosing panenc

113 diasis (n = 10), cryptococcosis (n = 9), and histoplasmosis (n = 11) revealed three antigens with rel

114 s treated with infliximab, manifestations of histoplasmosis occurred within 1 week to 6 months after

115 ransplant (SOT), we report a large series of histoplasmosis occurring after SOT.

116 on three patients who developed disseminated histoplasmosis on therapy with TNF-alpha inhibitors.

117 While much is known about histoplasmosis, only a single virulence factor has been

118 No reactivity was detected with sera from histoplasmosis or blastomycosis patients.

119 Active histoplasmosis or undiagnosed and presumably asymptomati

120 sera from patients with coccidioidomycosis, histoplasmosis, or blastomycosis.

121 vestigate its potential for the follow-up of histoplasmosis patients during treatment, antigen titers

122 cognized by antibodies in 18 of 18 sera from histoplasmosis patients, but not by antibodies in sera f

123 formance for management of immunocompromised histoplasmosis patients.

124 elayed diagnosis of progressive disseminated histoplasmosis (PDH) results in high mortality rates.

125 Herein, we report a case of isolated CNS histoplasmosis presenting with pontine stroke and mening

126 e the understanding of genetic influences on histoplasmosis, reveal how shifts in the composition of

127 Histoplasmosis should be considered early in the evaluat

128 Sera from four patients with disseminated histoplasmosis showed falls in antigen levels; three of

129 In contrast, in secondary histoplasmosis, significant elevations of IL-4 and -10 w

130 The Verteporfin in Ocular Histoplasmosis study evaluated photodynamic therapy for

131 MD) (12), macular hole (10), presumed ocular histoplasmosis syndrome (6), proliferative diabetic reti

132 Presumed ocular histoplasmosis syndrome classically presents with atroph

133 streaks, and idiopathy, and presumed ocular histoplasmosis syndrome is still under investigation.

134 roidal neovascularization in presumed ocular histoplasmosis syndrome or age-related macular degenerat

135 macular degeneration or the presumed ocular histoplasmosis syndrome or retinal neovascularization fr

136 Presumed ocular histoplasmosis syndrome remains a significant cause of v

137 The pathogenesis of presumed ocular histoplasmosis syndrome remains mysterious; although som

138 (age-related macular degeneration or ocular histoplasmosis syndrome).

139 al for patients with angioid streaks, ocular histoplasmosis syndrome, and idiopathic causes of choroi

140 surgery in the management of presumed ocular histoplasmosis syndrome, however.

141 n Histoplasma capsulatum and presumed ocular histoplasmosis syndrome, other reports document nearly i

142 ed debate on the etiology of presumed ocular histoplasmosis syndrome, there have been significant adv

143 shown to be associated with Presumed Ocular Histoplasmosis Syndrome-related choroidal neovasculariza

144 he blinding complications of presumed ocular histoplasmosis syndrome.

145 reatment of complications of presumed ocular histoplasmosis syndrome.

146 cularization associated with presumed ocular histoplasmosis syndrome.

147 usly shown in a murine model of disseminated histoplasmosis that IL-12, IFN-gamma, and TNF-alpha were

148 With use of a murine model of histoplasmosis, this study establishes that methamphetam

149 In reinfection histoplasmosis, treatment with anti-IL-12 MAb did not al

150 In murine histoplasmosis, tumor necrosis factor alpha (TNF-alpha)

151 A case of acute histoplasmosis was defined as an influenza-like illness

152 herapy while she was living in an area where histoplasmosis was endemic was thought to be the most li

153 terleukin (IL)-12 on the course of pulmonary histoplasmosis was examined in naive and immune mice.

154 hotericin B monotherapy for treatment of CNS histoplasmosis was not supported by this study.

155 In this study, histoplasmosis was reactivated by the depletion of CD4 a

156 production of nitric oxide during secondary histoplasmosis was similar in both groups.

157 A murine model of CNS histoplasmosis was used to evaluate the hypothesis that

158 vision loss in patients with presumed ocular histoplasmosis, well defined extrafoveal or juxtafoveal

159 atients with acute pulmonary or disseminated histoplasmosis were also positive.

160 individuals with culture- and antigen-proven histoplasmosis were evaluated using the LAMP assay.

161 presenting with different clinical forms of histoplasmosis were monitored at regular intervals for u

162 healthy persons (n = 10) without evidence of histoplasmosis were used as assay controls.

163 ated macular degeneration or presumed ocular histoplasmosis, whereas both alpha v beta 3 and alpha v

164 HPH mutant was avirulent in a mouse model of histoplasmosis, whereas the vma1/VMA1 strain was as path

165 Ten percent of patients died due to histoplasmosis with 72% of deaths occurring in the first

166 rrently available laboratory diagnostics for histoplasmosis, with an emphasis on complexities of test